Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Laurie Gaspar

Concepts (490)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Brain Neoplasms
101
2025
1318
6.010
 Why?
Lung Neoplasms
92
2025
2637
4.930
 Why?
Carcinoma, Non-Small-Cell Lung
54
2022
1180
3.860
 Why?
Radiosurgery
44
2022
400
3.620
 Why?
Cranial Irradiation
21
2025
85
2.800
 Why?
Small Cell Lung Carcinoma
12
2025
119
2.620
 Why?
Combined Modality Therapy
62
2022
1264
1.190
 Why?
Radiation Pneumonitis
5
2021
31
1.160
 Why?
Radiotherapy, Intensity-Modulated
9
2018
141
1.140
 Why?
Carcinoma, Small Cell
8
2007
173
1.070
 Why?
Antineoplastic Combined Chemotherapy Protocols
30
2023
1953
1.030
 Why?
Neoplasm Staging
39
2020
1461
1.020
 Why?
Radiotherapy Dosage
39
2023
289
0.990
 Why?
Chemoradiotherapy
8
2020
237
0.950
 Why?
Practice Guidelines as Topic
11
2021
1559
0.940
 Why?
Brachytherapy
12
2017
134
0.880
 Why?
Radiotherapy Planning, Computer-Assisted
11
2021
149
0.840
 Why?
Radiation Oncology
12
2022
87
0.820
 Why?
Glioblastoma
18
2016
353
0.810
 Why?
Neoplasm Recurrence, Local
21
2017
1137
0.800
 Why?
Adenocarcinoma
13
2022
927
0.680
 Why?
Glioma
15
2015
425
0.680
 Why?
Aged
103
2025
25850
0.650
 Why?
Esophageal Neoplasms
9
2008
346
0.650
 Why?
Survival Rate
31
2018
2088
0.650
 Why?
Liver Neoplasms
8
2009
780
0.640
 Why?
Prognosis
45
2022
4278
0.640
 Why?
Humans
222
2025
144261
0.640
 Why?
Radiotherapy, Conformal
8
2017
74
0.630
 Why?
Radiotherapy
14
2017
206
0.610
 Why?
Clinical Trials as Topic
18
2018
1050
0.600
 Why?
Middle Aged
119
2025
35762
0.600
 Why?
Radiotherapy, Adjuvant
16
2022
222
0.600
 Why?
Neurosurgeons
1
2019
17
0.590
 Why?
Dacarbazine
9
2016
100
0.580
 Why?
Evidence-Based Medicine
10
2021
729
0.580
 Why?
Four-Dimensional Computed Tomography
6
2021
38
0.560
 Why?
Oncologists
1
2018
46
0.510
 Why?
Patient Selection
10
2019
719
0.510
 Why?
Carcinoma, Squamous Cell
10
2017
641
0.500
 Why?
Clinical Decision-Making
3
2021
358
0.480
 Why?
Cisplatin
18
2021
334
0.480
 Why?
Male
129
2025
72035
0.480
 Why?
Physician's Role
1
2018
218
0.480
 Why?
Aged, 80 and over
45
2020
8243
0.480
 Why?
Antineoplastic Agents, Alkylating
8
2016
72
0.470
 Why?
Female
132
2025
77976
0.460
 Why?
Antineoplastic Agents
20
2017
2192
0.460
 Why?
Induction Chemotherapy
2
2013
87
0.430
 Why?
Adult
91
2025
40262
0.410
 Why?
Receptor Protein-Tyrosine Kinases
5
2017
230
0.410
 Why?
Survival Analysis
24
2020
1382
0.400
 Why?
Physician-Patient Relations
1
2018
581
0.380
 Why?
Treatment Outcome
36
2021
11643
0.380
 Why?
Etoposide
12
2021
166
0.370
 Why?
Pro-Opiomelanocortin
7
1989
20
0.350
 Why?
Pneumonectomy
2
2015
169
0.340
 Why?
Astrocytoma
9
2014
129
0.330
 Why?
Retrospective Studies
40
2022
17009
0.320
 Why?
Melanoma
5
2018
760
0.310
 Why?
Whole-Body Irradiation
1
2009
76
0.300
 Why?
Societies, Medical
7
2021
886
0.300
 Why?
Pulmonary Ventilation
4
2021
83
0.300
 Why?
Guidelines as Topic
2
2020
267
0.300
 Why?
Protein Kinase Inhibitors
4
2021
968
0.300
 Why?
Chemotherapy, Adjuvant
12
2017
419
0.300
 Why?
Karnofsky Performance Status
11
2020
37
0.290
 Why?
ErbB Receptors
8
2022
627
0.290
 Why?
Guideline Adherence
4
2018
586
0.290
 Why?
Medical Oncology
7
2021
331
0.280
 Why?
Quinazolines
6
2014
266
0.280
 Why?
Dose-Response Relationship, Radiation
11
2019
140
0.280
 Why?
Iodine Radioisotopes
6
2006
136
0.270
 Why?
Lung
9
2021
4108
0.270
 Why?
Re-Irradiation
2
2018
9
0.270
 Why?
Breast Neoplasms
9
2020
2447
0.270
 Why?
Controlled Clinical Trials as Topic
1
2007
27
0.270
 Why?
Radiopharmaceuticals
5
2014
194
0.260
 Why?
Neoplasm Metastasis
8
2019
688
0.260
 Why?
Disease Progression
13
2018
2840
0.260
 Why?
Follow-Up Studies
22
2018
5389
0.250
 Why?
Anticonvulsants
2
2019
234
0.250
 Why?
Tumor Burden
9
2017
319
0.240
 Why?
Biomarkers, Tumor
6
2021
1313
0.240
 Why?
Paclitaxel
5
2011
255
0.230
 Why?
Tomography, X-Ray Computed
10
2018
2730
0.230
 Why?
Proto-Oncogene Proteins B-raf
2
2017
225
0.220
 Why?
Prospective Studies
22
2018
7970
0.220
 Why?
Spinal Cord
4
2018
380
0.220
 Why?
Steroids
2
2019
160
0.210
 Why?
Taxoids
5
2015
116
0.210
 Why?
Carcinoma
1
2006
227
0.200
 Why?
Lymphatic Metastasis
3
2017
333
0.200
 Why?
Central Nervous System
2
2017
281
0.200
 Why?
Gastrointestinal Neoplasms
3
2019
70
0.200
 Why?
Carcinoma, Renal Cell
3
2018
234
0.190
 Why?
Carcinoma, Hepatocellular
2
2005
370
0.190
 Why?
Magnetic Resonance Imaging
9
2019
3857
0.190
 Why?
Radiography
8
2014
842
0.180
 Why?
Necrosis
3
2019
244
0.180
 Why?
Medical Illustration
2
2012
10
0.180
 Why?
Randomized Controlled Trials as Topic
7
2021
1705
0.180
 Why?
Organs at Risk
2
2012
37
0.180
 Why?
Ribs
2
2012
35
0.170
 Why?
Positron Emission Tomography Computed Tomography
2
2020
117
0.170
 Why?
Brachial Plexus
2
2012
35
0.170
 Why?
Professional Staff Committees
4
2001
10
0.170
 Why?
Oligodendroglioma
4
2014
15
0.170
 Why?
Esophagectomy
1
2002
135
0.160
 Why?
Testicular Neoplasms
1
2022
113
0.160
 Why?
Neoplasms
6
2020
2870
0.160
 Why?
Mutation
4
2021
4085
0.160
 Why?
Peptide Fragments
4
1989
698
0.160
 Why?
Research Design
7
2018
1129
0.160
 Why?
Proportional Hazards Models
8
2020
1322
0.150
 Why?
Thymus Neoplasms
2
2017
27
0.150
 Why?
Metalloporphyrins
3
2011
66
0.150
 Why?
Thymoma
2
2017
36
0.150
 Why?
Hippocampus
1
2025
965
0.150
 Why?
Consolidation Chemotherapy
1
2019
10
0.150
 Why?
Esophagus
2
2012
261
0.150
 Why?
Maximum Tolerated Dose
6
2010
212
0.150
 Why?
Meningeal Neoplasms
3
2017
93
0.150
 Why?
Congresses as Topic
2
2019
221
0.150
 Why?
Quality of Life
6
2025
3166
0.150
 Why?
Time Factors
10
2019
7155
0.150
 Why?
Radiation Injuries
5
2015
151
0.150
 Why?
Expert Testimony
1
2019
42
0.140
 Why?
Watchful Waiting
1
2019
88
0.140
 Why?
Aquaporin 4
1
2019
98
0.140
 Why?
Gray Matter
1
2019
88
0.140
 Why?
Intracranial Arteriovenous Malformations
2
1995
53
0.130
 Why?
Spinal Neoplasms
1
2018
36
0.130
 Why?
CTLA-4 Antigen
1
2018
104
0.130
 Why?
Intersectoral Collaboration
1
2018
62
0.130
 Why?
Carboplatin
4
2011
160
0.130
 Why?
Endpoint Determination
1
2018
83
0.130
 Why?
Treatment Failure
5
2014
363
0.130
 Why?
Kidney Neoplasms
3
2018
412
0.130
 Why?
Professional Competence
1
2018
98
0.130
 Why?
Cognition
4
2013
1258
0.130
 Why?
Genes, ras
1
2017
96
0.130
 Why?
Decision Trees
1
1997
81
0.130
 Why?
Triazines
2
2009
49
0.120
 Why?
Pituitary Neoplasms
5
1994
190
0.120
 Why?
Proto-Oncogene Proteins c-kit
1
2017
72
0.120
 Why?
Antineoplastic Agents, Immunological
1
2019
199
0.120
 Why?
Interdisciplinary Communication
1
2018
197
0.120
 Why?
Mortality
1
2019
371
0.120
 Why?
Hemangioma, Cavernous
2
1993
13
0.120
 Why?
Fluorouracil
6
2004
235
0.120
 Why?
Brain
5
2019
2930
0.120
 Why?
Salvage Therapy
4
2017
162
0.120
 Why?
Programmed Cell Death 1 Receptor
1
2018
264
0.120
 Why?
Antibodies
1
2018
401
0.120
 Why?
Cohort Studies
7
2019
5935
0.120
 Why?
Pulmonary Atelectasis
1
2015
16
0.120
 Why?
Adrenal Cortex Hormones
1
2019
478
0.120
 Why?
Age Factors
8
2017
3313
0.120
 Why?
Accreditation
2
2013
101
0.110
 Why?
Patient Preference
1
2018
221
0.110
 Why?
Radiation-Sensitizing Agents
5
2009
43
0.110
 Why?
Medically Underserved Area
1
2016
100
0.110
 Why?
Antineoplastic Agents, Phytogenic
2
2006
177
0.110
 Why?
Radiographic Image Interpretation, Computer-Assisted
1
2015
120
0.110
 Why?
Postoperative Care
1
2017
288
0.110
 Why?
United States
13
2022
15876
0.110
 Why?
Central Nervous System Neoplasms
1
2017
173
0.110
 Why?
Carmustine
7
2010
52
0.100
 Why?
Analysis of Variance
5
2014
1304
0.100
 Why?
Perfusion Imaging
1
2014
65
0.100
 Why?
Fibrosarcoma
1
1993
23
0.100
 Why?
Risk Assessment
3
2021
3637
0.100
 Why?
Triple Negative Breast Neoplasms
1
2017
215
0.100
 Why?
Lymphoma, Large-Cell, Anaplastic
1
2014
22
0.100
 Why?
Camptothecin
2
2011
140
0.100
 Why?
Receptors, Progesterone
4
2020
356
0.100
 Why?
Contraindications
2
2008
91
0.100
 Why?
Nelson Syndrome
4
1987
5
0.100
 Why?
Cerebellar Neoplasms
2
1996
177
0.100
 Why?
Medulloblastoma
2
1996
215
0.100
 Why?
Adolescent
22
2017
22281
0.100
 Why?
Respiratory Function Tests
1
2015
546
0.100
 Why?
Kaplan-Meier Estimate
5
2019
964
0.100
 Why?
Disease-Free Survival
6
2014
768
0.100
 Why?
Pyrazoles
2
2014
509
0.090
 Why?
Gene Expression Regulation, Neoplastic
1
2019
1455
0.090
 Why?
beta-Endorphin
3
1989
4
0.090
 Why?
Pyridines
2
2014
605
0.090
 Why?
Radiotherapy, High-Energy
4
2000
18
0.090
 Why?
Particle Accelerators
1
1991
9
0.090
 Why?
Adrenocorticotropic Hormone
3
1989
147
0.090
 Why?
Pancreatic Neoplasms
1
2000
918
0.090
 Why?
Bone Neoplasms
3
2007
253
0.090
 Why?
Forced Expiratory Volume
2
2015
448
0.080
 Why?
Radiation Protection
2
2009
41
0.080
 Why?
Quality Assurance, Health Care
3
2009
336
0.080
 Why?
Hyperthermia, Induced
1
1992
121
0.080
 Why?
Young Adult
8
2017
13990
0.080
 Why?
Technology, Radiologic
1
2010
6
0.080
 Why?
Radiotherapy, Computer-Assisted
1
2010
12
0.080
 Why?
Bevacizumab
3
2015
167
0.080
 Why?
MEDLINE
1
2009
20
0.080
 Why?
Spine
1
1991
182
0.080
 Why?
Databases, Factual
5
2017
1484
0.080
 Why?
Clinical Trials, Phase II as Topic
2
2002
77
0.080
 Why?
Multivariate Analysis
6
2020
1533
0.080
 Why?
Neurosurgery
1
2009
41
0.080
 Why?
Severity of Illness Index
2
2008
2917
0.080
 Why?
Adrenal Medulla
1
1989
9
0.070
 Why?
Adenoma
4
1994
218
0.070
 Why?
Neurotensin
1
1989
13
0.070
 Why?
Drug Therapy
1
2009
80
0.070
 Why?
Risk Factors
7
2021
10699
0.070
 Why?
Fractures, Spontaneous
1
1988
15
0.070
 Why?
Piperidines
1
2010
217
0.070
 Why?
Meta-Analysis as Topic
1
2009
172
0.070
 Why?
Ependymoma
2
2009
176
0.070
 Why?
Catheter Ablation
1
2012
353
0.070
 Why?
Esophageal Fistula
2
2000
21
0.070
 Why?
Equipment Failure Analysis
1
2009
128
0.070
 Why?
Imaging, Three-Dimensional
2
2010
582
0.070
 Why?
Pheochromocytoma
1
1989
58
0.070
 Why?
Humeral Fractures
1
1988
46
0.070
 Why?
Radionuclide Imaging
1
2008
112
0.070
 Why?
Liver
2
2008
1884
0.070
 Why?
Education, Medical, Graduate
1
2013
557
0.070
 Why?
Respiratory Mechanics
1
2008
72
0.070
 Why?
Lymph Node Excision
1
2009
173
0.070
 Why?
Adrenal Gland Neoplasms
1
1989
91
0.070
 Why?
Positron-Emission Tomography
2
2008
323
0.070
 Why?
Femoral Fractures
1
1988
82
0.070
 Why?
Craniopharyngioma
1
2009
77
0.070
 Why?
Chromatography, Gel
4
1989
129
0.070
 Why?
Palliative Care
5
2018
996
0.070
 Why?
Pulmonary Disease, Chronic Obstructive
1
2015
919
0.070
 Why?
Surveys and Questionnaires
2
2018
6021
0.060
 Why?
Kidney
2
2005
1495
0.060
 Why?
Statistics, Nonparametric
2
2018
427
0.060
 Why?
Radioimmunoassay
4
1989
165
0.060
 Why?
Vascular Diseases
1
2009
250
0.060
 Why?
Genetic Markers
2
2017
331
0.060
 Why?
Whole Body Imaging
1
2006
26
0.060
 Why?
Uterine Cervical Neoplasms
1
1989
267
0.060
 Why?
Biomedical Research
2
2009
709
0.060
 Why?
Hepatitis B, Chronic
1
2005
22
0.060
 Why?
Neoplasm Grading
2
2020
307
0.060
 Why?
Seizures
1
2009
460
0.060
 Why?
Linear Models
3
2017
850
0.060
 Why?
Drug Administration Schedule
3
2014
778
0.060
 Why?
Strontium Radioisotopes
2
2006
3
0.060
 Why?
Vascular Endothelial Growth Factor A
1
2008
557
0.060
 Why?
Diagnostic Imaging
3
2009
338
0.060
 Why?
Databases as Topic
1
2005
71
0.060
 Why?
Gene Rearrangement
2
2018
155
0.060
 Why?
Delivery of Health Care
1
2012
940
0.060
 Why?
Clinical Competence
1
2013
1241
0.060
 Why?
Consensus
2
2021
488
0.060
 Why?
Hemoglobins
1
2007
383
0.050
 Why?
Antiemetics
1
2005
49
0.050
 Why?
Pituitary Hormones
1
1984
15
0.050
 Why?
Immunotherapy
2
2022
652
0.050
 Why?
Organ Size
1
2005
462
0.050
 Why?
Peptides
3
1985
995
0.050
 Why?
Physicians
1
2013
938
0.050
 Why?
Body Fluids
1
1985
70
0.050
 Why?
Retreatment
3
2012
77
0.050
 Why?
Anticoagulants
1
2009
721
0.050
 Why?
Cognition Disorders
2
2010
537
0.050
 Why?
Age Distribution
1
2005
397
0.050
 Why?
Dexamethasone
3
2012
370
0.050
 Why?
Sex Distribution
1
2005
380
0.050
 Why?
Practice Patterns, Physicians'
1
2013
1347
0.050
 Why?
Regression Analysis
2
2017
998
0.050
 Why?
Hepatitis C, Chronic
1
2005
152
0.050
 Why?
Erlotinib Hydrochloride
2
2014
72
0.050
 Why?
Feasibility Studies
3
2011
1087
0.050
 Why?
Liver Cirrhosis
1
2005
288
0.050
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2006
257
0.050
 Why?
Propionates
1
2003
39
0.050
 Why?
Chromatography, Affinity
3
1989
85
0.050
 Why?
Preoperative Care
1
2005
379
0.050
 Why?
Internship and Residency
1
2013
1255
0.050
 Why?
Aniline Compounds
1
2003
119
0.050
 Why?
Societies
1
2022
40
0.050
 Why?
Clinical Trials, Phase III as Topic
2
2004
117
0.040
 Why?
Pterygium
1
2000
4
0.040
 Why?
Organizational Objectives
4
2001
66
0.040
 Why?
Algorithms
2
2017
1834
0.040
 Why?
Ontario
2
2017
96
0.040
 Why?
Esophagoscopy
1
2002
221
0.040
 Why?
Neurologic Examination
1
2000
130
0.040
 Why?
Reproducibility of Results
2
2015
3403
0.040
 Why?
Vincristine
2
2010
140
0.040
 Why?
B7-H1 Antigen
1
2022
241
0.040
 Why?
BRCA1 Protein
1
2020
81
0.040
 Why?
Carcinoma, Bronchogenic
1
1999
20
0.040
 Why?
Spinal Cord Neoplasms
1
1999
40
0.040
 Why?
Carcinoma, Large Cell
1
1999
17
0.040
 Why?
Neuropsychological Tests
3
2013
1129
0.040
 Why?
Receptors, Estrogen
2
2013
457
0.040
 Why?
Medical Records
2
2010
186
0.040
 Why?
Liver Transplantation
1
2005
822
0.030
 Why?
Reoperation
2
2012
629
0.030
 Why?
Urinary Bladder Neoplasms
1
2001
255
0.030
 Why?
Estrogens
1
2020
380
0.030
 Why?
Thoracic Vertebrae
1
2018
79
0.030
 Why?
Iridium Radioisotopes
1
1997
4
0.030
 Why?
Epidemiologic Methods
1
2017
89
0.030
 Why?
Aziridines
2
1994
6
0.030
 Why?
Clinical Trials, Phase I as Topic
1
1997
52
0.030
 Why?
Colorado
3
2014
4562
0.030
 Why?
Child, Preschool
7
2009
11774
0.030
 Why?
Skin Neoplasms
2
2017
847
0.030
 Why?
Molecular Weight
2
1989
327
0.030
 Why?
Biopsy, Needle
1
2017
183
0.030
 Why?
Esophagitis
2
2009
66
0.030
 Why?
Benzoquinones
2
1994
47
0.030
 Why?
Respiration
1
2017
206
0.030
 Why?
Memory Disorders
2
2010
193
0.030
 Why?
Supratentorial Neoplasms
1
1996
18
0.030
 Why?
Precision Medicine
1
2020
456
0.030
 Why?
Neutropenia
2
2009
155
0.030
 Why?
Odds Ratio
1
1999
1072
0.030
 Why?
Heart
1
2020
633
0.030
 Why?
Meningioma
1
1997
86
0.030
 Why?
Propensity Score
1
2018
367
0.030
 Why?
Sex Factors
2
2014
2096
0.030
 Why?
Estrogen Receptor alpha
1
2017
161
0.030
 Why?
Cerebral Angiography
1
1995
119
0.030
 Why?
Forecasting
3
2001
388
0.030
 Why?
Pilot Projects
3
2015
1867
0.030
 Why?
Myocardium
1
2020
939
0.030
 Why?
Marital Status
1
2014
46
0.030
 Why?
Technetium Tc 99m Pentetate
1
2014
7
0.030
 Why?
Ventilation-Perfusion Ratio
1
2014
12
0.030
 Why?
Nuclear Medicine
1
2014
9
0.030
 Why?
Vital Capacity
1
2015
290
0.030
 Why?
Radioisotope Teletherapy
1
1993
2
0.030
 Why?
Molecular Targeted Therapy
1
2017
431
0.030
 Why?
Cobalt Radioisotopes
1
1993
7
0.030
 Why?
Patient Safety
1
2017
347
0.030
 Why?
Nervous System Diseases
1
1997
282
0.030
 Why?
Texas
1
2014
278
0.030
 Why?
Spatial Analysis
1
2013
23
0.030
 Why?
Child
9
2009
22537
0.020
 Why?
SEER Program
1
2014
224
0.020
 Why?
Vimentin
1
1993
54
0.020
 Why?
Developing Countries
1
2016
314
0.020
 Why?
Radiodermatitis
1
1993
11
0.020
 Why?
Prostatic Neoplasms
1
2001
974
0.020
 Why?
Radiometry
1
2013
56
0.020
 Why?
Monte Carlo Method
1
2013
155
0.020
 Why?
Observer Variation
1
2014
354
0.020
 Why?
Scalp
1
1993
37
0.020
 Why?
Cerebral Cortex
1
1996
464
0.020
 Why?
Protein-Tyrosine Kinases
1
2016
433
0.020
 Why?
Time
1
2013
86
0.020
 Why?
Mitosis
1
1993
199
0.020
 Why?
Medical Errors
1
2013
118
0.020
 Why?
Radiation Dosage
1
2013
192
0.020
 Why?
Remission Induction
2
2008
306
0.020
 Why?
Ascorbic Acid
1
1993
179
0.020
 Why?
Radiology
1
2014
173
0.020
 Why?
Disease Management
1
2016
643
0.020
 Why?
International Agencies
1
2011
30
0.020
 Why?
Diagnosis, Differential
1
2015
1487
0.020
 Why?
Breast Neoplasms, Male
1
2011
29
0.020
 Why?
Electrons
1
1991
88
0.020
 Why?
Bronchography
1
2010
10
0.020
 Why?
Fibrosis
1
2013
547
0.020
 Why?
Infusions, Intravenous
2
2004
423
0.020
 Why?
Sensitivity and Specificity
1
2015
1983
0.020
 Why?
Procarbazine
1
1990
9
0.020
 Why?
Longitudinal Studies
1
2018
2926
0.020
 Why?
Lomustine
1
1990
15
0.020
 Why?
Cell Nucleus
1
1993
618
0.020
 Why?
Physics
1
2010
17
0.020
 Why?
Smoking
1
2017
1468
0.020
 Why?
Selection Bias
1
2009
38
0.020
 Why?
Clinical Trials Data Monitoring Committees
1
2009
3
0.020
 Why?
Neoplasm, Residual
1
2010
139
0.020
 Why?
Hypophysectomy
1
1989
15
0.020
 Why?
Quality Control
1
2010
163
0.020
 Why?
Immunohistochemistry
1
1993
1715
0.020
 Why?
Chromatin
1
1993
561
0.020
 Why?
Platinum
1
2009
50
0.020
 Why?
Incidence
1
2016
2870
0.020
 Why?
Adrenal Cortex
1
1989
33
0.020
 Why?
Prevalence
1
2016
2815
0.020
 Why?
Hepatic Veno-Occlusive Disease
1
2008
12
0.020
 Why?
Neoplasms, Unknown Primary
1
1988
20
0.020
 Why?
Bronchi
1
2010
267
0.020
 Why?
beta-Lipotropin
2
1985
2
0.020
 Why?
Certification
1
2010
119
0.020
 Why?
Prostheses and Implants
1
2010
141
0.020
 Why?
Liver Regeneration
1
2008
46
0.020
 Why?
Polymorphism, Single Nucleotide
1
2016
2143
0.020
 Why?
Endorphins
2
1985
9
0.020
 Why?
Anti-Inflammatory Agents
1
2012
474
0.020
 Why?
Epinephrine
1
1989
155
0.020
 Why?
Fracture Fixation, Intramedullary
1
1988
60
0.020
 Why?
Motion
1
2008
100
0.020
 Why?
Administration, Oral
1
2010
847
0.020
 Why?
International Cooperation
1
2008
197
0.020
 Why?
Mental Status Schedule
1
2007
35
0.020
 Why?
Reference Values
1
1989
797
0.020
 Why?
Genetic Predisposition to Disease
1
2016
2359
0.020
 Why?
Infant
4
1999
10022
0.020
 Why?
Creatinine
1
1989
505
0.020
 Why?
Bleomycin
1
2009
253
0.020
 Why?
Rectal Neoplasms
1
2008
156
0.020
 Why?
Predictive Value of Tests
2
2008
2111
0.020
 Why?
Chromatography, High Pressure Liquid
1
1989
593
0.020
 Why?
Southwestern United States
1
2006
95
0.020
 Why?
California
1
2008
469
0.020
 Why?
Neovascularization, Pathologic
1
2008
286
0.020
 Why?
Chromium Compounds
1
2006
2
0.020
 Why?
Glucocorticoids
1
2010
533
0.020
 Why?
Polycythemia Vera
1
2006
8
0.020
 Why?
Sodium Iodide
1
2006
3
0.010
 Why?
Pleural Effusion, Malignant
1
2006
12
0.010
 Why?
Hydrocephalus
1
1987
111
0.010
 Why?
Hyperthyroidism
1
2006
21
0.010
 Why?
Patient Isolation
1
2006
20
0.010
 Why?
Ascites
1
2006
49
0.010
 Why?
Yttrium Radioisotopes
1
2006
64
0.010
 Why?
Methadone
1
1987
110
0.010
 Why?
DNA Repair
1
2008
255
0.010
 Why?
DNA Damage
1
2008
428
0.010
 Why?
Concanavalin A
1
1985
71
0.010
 Why?
Chromatography
1
1985
27
0.010
 Why?
Organophosphorus Compounds
1
2006
84
0.010
 Why?
Phosphates
1
2006
179
0.010
 Why?
ACTH Syndrome, Ectopic
1
1984
1
0.010
 Why?
Occipital Lobe
1
2004
26
0.010
 Why?
Organometallic Compounds
1
2006
112
0.010
 Why?
Lymphoma, Non-Hodgkin
1
2006
124
0.010
 Why?
Biotransformation
1
1984
62
0.010
 Why?
Patient Education as Topic
1
2010
777
0.010
 Why?
Carbohydrate Metabolism
1
1984
60
0.010
 Why?
Brain Edema
1
2004
62
0.010
 Why?
Thrombocytopenia
1
2006
205
0.010
 Why?
Arginine Vasopressin
1
1984
44
0.010
 Why?
Genomics
1
2009
833
0.010
 Why?
Recurrence
2
2000
1134
0.010
 Why?
Vomiting
1
2004
130
0.010
 Why?
Corticotropin-Releasing Hormone
1
1984
72
0.010
 Why?
Oils
1
1983
22
0.010
 Why?
Motor Skills
1
2004
104
0.010
 Why?
Bipolar Disorder
1
1985
280
0.010
 Why?
Thyroid Neoplasms
1
2006
343
0.010
 Why?
Immunologic Factors
1
2003
255
0.010
 Why?
Pain
1
2006
777
0.010
 Why?
Antimetabolites, Antineoplastic
1
2001
105
0.010
 Why?
Psychometrics
1
2004
730
0.010
 Why?
Postoperative Period
1
2000
353
0.010
 Why?
Apoptosis
1
2008
2430
0.010
 Why?
Thorax
1
1999
50
0.010
 Why?
Opioid-Related Disorders
1
1987
576
0.010
 Why?
Michigan
1
1999
136
0.010
 Why?
Cysts
1
1999
111
0.010
 Why?
Bias
1
1999
201
0.010
 Why?
Antibodies, Monoclonal
1
2006
1519
0.010
 Why?
Mercaptopurine
1
1996
15
0.010
 Why?
Mitomycin
1
1996
32
0.010
 Why?
Meninges
1
1997
49
0.010
 Why?
Biopsy
1
1999
1075
0.010
 Why?
Cross-Sectional Studies
1
2007
5813
0.010
 Why?
Autoantibodies
1
1983
1497
0.010
 Why?
Cause of Death
1
1996
464
0.010
 Why?
Decision Making
1
2001
974
0.010
 Why?
Solutions
1
1993
166
0.010
 Why?
Neoplasms, Radiation-Induced
1
1993
99
0.010
 Why?
Cerebral Hemorrhage
1
1993
120
0.010
 Why?
Computer Simulation
1
1995
1025
0.010
 Why?
Patient Compliance
1
1994
585
0.000
 Why?
Evaluation Studies as Topic
1
1989
166
0.000
 Why?
Double-Blind Method
1
1993
2025
0.000
 Why?
Melanocyte-Stimulating Hormones
1
1985
3
0.000
 Why?
Lithium
1
1985
42
0.000
 Why?
Postoperative Complications
1
1996
2916
0.000
 Why?
Brassica
1
1983
5
0.000
 Why?
Spain
1
1983
48
0.000
 Why?
Antigen-Antibody Complex
1
1983
72
0.000
 Why?
Drug Synergism
1
1984
357
0.000
 Why?
Syndrome
1
1983
380
0.000
 Why?
In Vitro Techniques
1
1984
1047
0.000
 Why?
Sheep
1
1984
880
0.000
 Why?
Animals
1
1984
38030
0.000
 Why?
Gaspar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (490) concept(s)
_
Co-Authors Expand Description
See all (35) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)